Entera Bio expands OPKO pact to include oral LA-PTH; appoints OPKO exec Rubin to board

Entera Bio Ltd.

Expanded collaboration covers once-daily oral LA-PTH tablet for hypoparathyroidism; 50/50 cost sharing.
IND filing for LA-PTH expected late 2026 after positive PK/PD data in December 2025.
Gerry Ostrov resigned as director effective Feb 1, 2026; Steven Rubin appointed as Class III director.
Rubin also chairs audit committee and serves on compensation committee; he is EVP at OPKO.
Oral OXM program progressing; Phase 1 injectable OXM data expected late 2026.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Entera Bio Ltd. amended Amended and Restated Collaboration and License Agreement with OPKO Health, Inc. and OPKO Biologics Ltd. (effective 2026-02-03).

Action: amendment
Agreement: collaboration
Counterparty: OPKO Health, Inc. and OPKO Biologics Ltd.
Effective: 2026-02-03

Exact text from the filing

On February 3, 2026, the Company and OPKO entered into an amended and restated collaboration and license agreement (the “ A&R Collaboration Agreement ”), which amends and restates the Original Collaboration Agreement to expand the scope of the agreement to include the collaboration with respect to the preclinical and clinical development of a daily long acting PTH tablet (“ LA-PTH ”) for the treatment of hypoparathyroidism and other indications in addition to the original oral dual agonist GLP-1/glucagon peptide program .

View on SEC.gov

329 material agreements filed in the last 30 days. Browse all material agreements →

Entera Bio Ltd. filing history →

Source: SEC EDGAR

accession 0001178913-26-000300

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.